ABAC Therapeutics

About ABAC Therapeutics

ABAC Therapeutics, established in Barcelona, Spain in 2014, is a biopharmaceutical company concentrating on the development of targeted therapies for multi-drug resistant (MDR) bacterial infections. The company was founded by Domingo Gargallo-Viola, who serves as the Chief Scientific Officer, and Albert Palomer, the Chief Executive Officer. Their work addresses the critical need for new treatments for infections caused by "superbugs," a threat highlighted by global health organizations.

The firm's core is its proprietary drug discovery platform, PasNas. This technology is designed to identify novel, pathogen-specific antibiotics that selectively eliminate multi-drug resistant bacteria. A key benefit of this precision medicine approach is the potential to minimize harm to the patient's normal microbiome and reduce the likelihood of developing further resistance. The business model is typical for an early-stage biopharma company, focusing on research and development with the goal of advancing drug candidates through clinical trials. Revenue generation will likely occur through licensing agreements, partnerships with larger pharmaceutical companies, or the eventual commercialization of their proprietary drugs.

A significant milestone for ABAC Therapeutics was a €16 million Series A funding round in February 2018. This financing was led by Pontifax and included participation from several venture capital firms and strategic investors such as the Global Health Science Fund, Caixa Capital Risc, and Debiopharm Innovation Fund. These funds were earmarked to advance the company's lead program into clinical development and to broaden its pipeline of pathogen-specific antibiotics. The lead program specifically targets Acinetobacter baumannii, a pathogen identified by the World Health Organization as a top priority for new drug development. In November 2019, the company was acquired by TIBIDABO VENTURES.